Literature DB >> 2807184

Thin regressing malignant melanoma: significance of concurrent regional lymph node metastases.

H M Shaw1, S W McCarthy, W H McCarthy, J F Thompson, G W Milton.   

Abstract

We attempted to clarify the prevailing controversy regarding the significance of regression in thin (less than 0.76 mm) primary melanomas. Of 7540 patients with cutaneous melanomas treated at the Sydney Melanoma Unit, 28 first presented with a thin primary lesion and concurrent regional lymph node metastases (stage II). Major differences in tumour histology existed between these patients and stage I patients with thin lesions that subsequently recurred. Regression was present in all 28 lesions in stage II patients. In 61 stage I patients ultimately developing a recurrence, 67% of lesions displayed regression. Significantly, however, in 735 stage I patients ultimately not developing a recurrence, 61% of lesions also displayed regression. Why regression occurs so frequently in thin lesions which never recur is unclear. Our results suggest that the histology of thin primary melanomas may be influenced by the presence or absence of metastases in patients at that time.

Entities:  

Mesh:

Year:  1989        PMID: 2807184     DOI: 10.1111/j.1365-2559.1989.tb03076.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  13 in total

1.  The significance of inflammation and regression in melanoma.

Authors:  M G Cook
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

Review 2.  Regressing thin cutaneous malignant melanomas (< or = 1.0 mm) are associated with angiogenesis.

Authors:  R L Barnhill; M A Levy
Journal:  Am J Pathol       Date:  1993-07       Impact factor: 4.307

3.  Regression in primary cutaneous melanoma: etiopathogenesis and clinical significance.

Authors:  Phyu P Aung; Priyadharsini Nagarajan; Victor G Prieto
Journal:  Lab Invest       Date:  2017-02-27       Impact factor: 5.662

4.  Outcome of sentinel lymph node biopsy and prognostic implications of regression in thin malignant melanoma.

Authors:  Susannah E McClain; Amber L Shada; Megan Barry; James W Patterson; Craig L Slingluff
Journal:  Melanoma Res       Date:  2012-08       Impact factor: 3.599

5.  Risk Factors for Lymphatic and Hematogenous Dissemination in Patients With Stages I to II Cutaneous Melanoma.

Authors:  Laura Calomarde-Rees; Rosario García-Calatayud; Celia Requena Caballero; Esperanza Manrique-Silva; Víctor Traves; Zaida García-Casado; Virtudes Soriano; Rajiv Kumar; Eduardo Nagore
Journal:  JAMA Dermatol       Date:  2019-06-01       Impact factor: 10.282

6.  Cutaneous melanomas exhibiting unusual biologic behavior.

Authors:  H M Shaw; J K Rivers; S W McCarthy; W H McCarthy
Journal:  World J Surg       Date:  1992 Mar-Apr       Impact factor: 3.352

7.  [Regression in malignant melanoma. Definition, etiopathogenesis, morphology and differential diagnosis].

Authors:  B E Paredes
Journal:  Pathologe       Date:  2007-11       Impact factor: 1.011

8.  Melanoma patients with unknown primary site or nodal recurrence after initial diagnosis have a favourable survival compared to those with synchronous lymph node metastasis and primary tumour.

Authors:  Benjamin Weide; Christine Faller; Margrit Elsässer; Petra Büttner; Annette Pflugfelder; Ulrike Leiter; Thomas Kurt Eigentler; Jürgen Bauer; Friedegund Meier; Claus Garbe
Journal:  PLoS One       Date:  2013-06-25       Impact factor: 3.240

9.  Early detection of tumour immune-rejection using magnetic resonance imaging.

Authors:  D-E Hu; D A Beauregard; M C Bearchell; L L Thomsen; K M Brindle
Journal:  Br J Cancer       Date:  2003-04-07       Impact factor: 7.640

10.  Cutaneous Melanoma with Brain Metastasis: Report of 193 Patients with New Observations.

Authors:  Alenka Gugger; Raymond L Barnhill; Burkhardt Seifert; Silvia Dehler; Holger Moch; Claire Lugassy; Ewerton Marques-Maggio; Elisabeth J Rushing; Daniela Mihic-Probst
Journal:  PLoS One       Date:  2016-05-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.